Profile
Muriel Haim is currently a Director at Neovacs SA since 2021 and a Director at GenetikaPlus Ltd. since 2018.
Previously, she worked as a Communication Manager at Sanofi Corp.
and as a VP-Outcome Research Worldwide at Merck & Co., Inc. from 1996 to 2001.
Dr. Haim is a graduate of Université Paris Dauphine-PSL.
Muriel Haim active positions
| Companies | Position | Start |
|---|---|---|
| NEOVACS | Director/Board Member | 01/02/2021 |
GenetikaPlus Ltd.
GenetikaPlus Ltd. Packaged SoftwareTechnology Services Develops precision medicine tool for depressive disorder patients | Director/Board Member | 01/01/2018 |
Former positions of Muriel Haim
| Companies | Position | End |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2001 |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Public Communications Contact | - |
| SANOFI | Public Communications Contact | - |
Training of Muriel Haim
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Neovacs SA
Neovacs SA Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapies | Health Technology |
Université Paris Dauphine-PSL
Université Paris Dauphine-PSL Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Health Technology |
GenetikaPlus Ltd.
GenetikaPlus Ltd. Packaged SoftwareTechnology Services Develops precision medicine tool for depressive disorder patients | Technology Services |
- Stock Market
- Insiders
- Muriel Haim
















